Latest Manufacturing News

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

Noumi Limited reported a 9.0% increase in revenue to $162.4 million for Q1 FY26, driven by strong growth in Dairy and Nutritionals and Milklab plant-based milks, while successfully closing legacy legal matters.

Evion Group advances its Maniry Graphite Project in Madagascar and expandable graphite JV in India, backed by a strategic US investor and EU recognition. The company is poised to expand production and supply critical minerals to key global markets amid rising demand.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Korvest has reported a record $13.2 million profit for FY25, driven by strong performances in its EzyStrut and Galvanising divisions, and is now embarking on a major expansion of its Kilburn manufacturing site.

Uscom Limited reported a 27% drop in cash reserves for Q1 2025, driven by declining revenue and rising costs, while preparing to sell its main business unit to stabilize finances.

Electro Optic Systems (EOS) reports a surge in contract backlog to $415 million, anchored by a landmark $125 million export order for a high-energy laser weapon. Despite a $34.3 million operating cash outflow in Q3, EOS is poised for growth with new defence contracts and product innovations.

Pure Hydrogen Corporation reported strong commercial momentum in the September 2025 quarter, securing multiple hydrogen vehicle orders across Australia and the US, expanding international distribution, and raising fresh capital to fuel growth.

International Graphite Limited has made significant strides in its global graphite strategy, signing a German joint venture and securing $3 million in US institutional funding to support its expanding mine-to-market operations.

Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.

The Treasurer has expressed preliminary concerns that Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma could harm Australia’s economy, citing plans to close a key Adelaide manufacturing site. Mayne Pharma disputes these claims and urges a resolution before the scheme deadline.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.